CVE-2025-14714: An Authentication Bypass vulnerability existed where the application bundled an interpreter (Python) that inhe
CVE-2025-14714 is a medium-severity flaw (CVSS 6.5) affecting libreoffice. Below: why it ranks where it does, which versions are affected, what to do, and the exact commands.
An Authentication Bypass vulnerability existed where the application bundled an interpreter (Python) that inherits the Transparency, Consent, and Control (TCC) permissions granted by the user to the main application bundle By executing the bundled interpreter directly the attacker's scripts run with the application's TCC privileges In fixed versions parent-constraints are used to allow only the main application to launch interpreter with
Why this priority
- No elevated risk signals yet
A fixed release or distro patch exists.
Risk facts
| CVSS score | 6.5 (Medium) |
| Attack vector | Local |
| Attack complexity | Low |
| Privileges needed | Low |
| User interaction | None |
| EPSS exploit chance | 0.1% (top 97%) |
| CISA exploited list | No |
| Weakness | CWE-288 |
| Published | 2025-12-15 |
| Last modified | 2026-10-23 |
Am I affected?
Timeline
- Published CVE record published
- Updated Record last modified
Scores and fixes here are computed automatically from those and other public sources. Confirm with the vendor advisory before changing production systems.
Quick answers
How do I fix CVE-2025-14714?
libreoffice: upgrade to 25.2.4.1. Exact commands for each OS are on this page.
Is CVE-2025-14714 being exploited?
CVE-2025-14714 is not on the CISA Known Exploited Vulnerabilities list at the time of the last update. Check again, as this can change.
What does CVE-2025-14714 affect?
CVE-2025-14714 affects libreoffice. Severity is medium (CVSS 6.5). An Authentication Bypass vulnerability existed where the application bundled an interpreter (Python) that inherits the Transparency, Consent, and Control (TCC) permissions granted by the user to the main application bundle By executing
How urgent is CVE-2025-14714?
Priority 23/100. No elevated risk signals yet.